Reviva reports FY2022 net loss of $24.3M; cash runway through Q3 2023; Phase 3 topline data expected mid-2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.
Cash and equivalents $18.5M as of Dec 31, 2022, down from $29.7M; cash expected to fund operations through Q3 2023.
Over 50% of ~400 patients enrolled in pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
Completed majority of prelaunch studies for NDA submission; positive drug-drug interaction data reported.
May initiate Phase 2a studies in bipolar disorder, MDD, ADHD in H2 2023 subject to additional financing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported full year ended December 31, 2022 results: net income approximately $24.3 million, EPS $1.25 per share.

Period: full year ended December 31, 2022
Net income: approximately $24.3 million
EPS: $1.25 per share
Result: reported results

Exact text from the filing

For the year ended December 31, 2022, net loss was approximately $24.3 million, or $1.25 per share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-008498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.